Overview
PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients
indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib
The primary objective of this Drug Use Examination (DUE) is to evaluate safety of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.
The secondary objective of this DUE is to evaluate effectiveness of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.
Eligibility
Inclusion Criteria:
The main criteria for inclusion of this DUE is the same as the approved package insert of
POMALYST® in Korea. Based on the current PI, patients who are treated with POMALYST® based
on the following criteria, can be registered into this DUE.
- POMALYST® in combination with dexamethasone is indicated in the treatment of patients
with relapsed and refractory multiple myeloma who have received at least two prior
treatment regimens, including both lenalidomide and bortezomib.
The actual inclusion criteria and patient population who can start with POMALYST® treatment
will be narrowed down according to the local health insurance reimbursement condition.
Exclusion Criteria:
- There's no exclusion criteria